A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Trial Profile

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 29 Apr 2020 to 30 Jun 2020.
    • 24 Nov 2017 Planned primary completion date changed from 29 Apr 2020 to 30 Jun 2020.
    • 24 Nov 2017 Planned initiation date changed from 30 Oct 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top